DiscoveryBioMed company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Grant - III | Alive

Total Raised


Last Raised

$1.6M | 7 yrs ago

About DiscoveryBioMed

DiscoveryBioMed (DBM) is a life sciences and biotechnology company. DiscoveryBioMed's mission is to fill a critical niche within the drug discovery industry by specializing in custom human cell engineering and human cell-based drug discovery. Its R&D infrastructure and know-how are leveraged as a CRO service to support the commercial and academic drug discovery community by integrating human cell platforms at any and all points within the drug discovery critical path, from HTS assay development and optimization to lead prioritization and progression, with the end product being 'high value' clinical candidates.

DiscoveryBioMed Headquarter Location

400 Riverhills Business Park Suite 435

Birmingham, Alabama, 35242,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing DiscoveryBioMed

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DiscoveryBioMed is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

838 items

DiscoveryBioMed Patents

DiscoveryBioMed has filed 5 patents.

patents chart

Application Date

Grant Date


Related Topics




Trifluoromethyl compounds, Rare diseases, Kidney diseases, Transcription factors, V8SuperTourer drivers


Application Date


Grant Date



Related Topics

Trifluoromethyl compounds, Rare diseases, Kidney diseases, Transcription factors, V8SuperTourer drivers



Latest DiscoveryBioMed News

TumorCube, a New Unit within DiscoveryBioMed, Will Use 3D Biogel-based Platforms to Perform 384-Well Plate-based Bioassays and 3D Bioreactor-driven Studies to Discover, Validate and Profile Anti-cancer Therapeutics on Human Cancer Cells

Jun 4, 2020

June 04, 2020 09:00 AM Eastern Daylight Time BIRMINGHAM, Ala.--( BUSINESS WIRE )--DiscoveryBioMed, Inc. (DBM, ) announces a new unit of its contract research organization (CRO) services business called TumorCube that is formed based upon our growing expertise in 3D Biogel-driven bioassays on diseased and normal human cell platform technologies. A trademark application has been filed. “DBM has a growing CRO services business in 3D Biogel-driven bioassays of diseased and normal human kidney cells. It is showcased prominently on our website, and we are proud to have many biotechnology companies and BioPharmaceutical organizations globally as our clients,” explained Dr. Erik Schwiebert, Ph.D., CEO of DBM. “We have now extended those offerings to include the assay of human urological cancers and endocrine-driven cancers such as ovarian cancers and breast cancers.” DBM is also assessing the feasibility of our 3D platforms for the assay of neurological and other cancers at present. DBM is utilizing existing human cancer cell lines in our initial technology optimization. “Interestingly, diseased human kidney cells and existing human cancer cell lines respond differently to specific lead therapeutic drugs or industry standard anti-cancer drugs when grown in 3D versus the traditional 2D tissue culture plastic-based assays,” explained Dr. Deborah Mai, DBM’s Chief Biological Officer. “DBM focuses on more physiological 3D growth formats as its preferred assay platforms and methods.” Not only does DBM wish to offer higher-throughput 3D assay platforms for hit-to-lead and lead oncology therapeutic profiling, DBM is optioning and licensing 3D bioreactor technology from the University of Alabama at Birmingham (UAB) that was invented by Dr. Joel Berry, Ph.D. in the Department of Biomedical Engineering to be a future platform for our TumorCube unit. “It has been exciting to collaborate with DBM on this commercial-academic partnership, and we are also excited to see TumorCube realized,” declared Dr. Berry. “We and DBM are also collaborating with investigators within the O’Neal Comprehensive Cancer Center at UAB on this platform development, which is an additional value add.” DBM is also pleased about continuing its local collaboration with UAB. “DBM has several current and past UAB-derived scientists that have contributed to the establishment and growth of our life sciences and biotechnology company, myself included,” explained Dr. Grace Salzer, a Senior Scientist and Business Development specialist. “DBM is fortunate to be collaborating with UAB scientists and technology transfer on this venture.” About DiscoveryBioMed, Inc. is in its 13th year of operation as a life sciences and biotechnology company focused on leveraging normal and diseased human cell platform technologies for its CRO services business and for its R&D programs. DBM and UAB are both located in Birmingham, AL where we seek a common goal of building a critical mass of biotechnology companies in a new hub of the Deep South. Contacts

DiscoveryBioMed Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

DiscoveryBioMed Rank

  • When was DiscoveryBioMed founded?

    DiscoveryBioMed was founded in 2007.

  • Where is DiscoveryBioMed's headquarters?

    DiscoveryBioMed's headquarters is located at 400 Riverhills Business Park, Birmingham.

  • What is DiscoveryBioMed's latest funding round?

    DiscoveryBioMed's latest funding round is Grant - III.

  • How much did DiscoveryBioMed raise?

    DiscoveryBioMed raised a total of $1.91M.

  • Who are DiscoveryBioMed's competitors?

    Competitors of DiscoveryBioMed include InterveXion Therapeutics, Cognition Therapeutics, Sequoia Sciences, ViaCyte, Five Prime Therapeutics, Carmot Therapeutics, Echelon Biosciences, Nuevolution, IRX Therapeutics, Cellix and 27 more.

You May Also Like

Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

Carmot Therapeutics

Carmot Therapeutics is applying its technology, Chemotype Evolution, to address unmet chemical needs in drug discovery, focusing on high-profile targets for which drug leads have been difficult to identify. Carmot has built and optimized this platform to rapidly and efficiently unlock therapeutic target space not currently accessible to conventional small molecule technologies. Carmot is currently using Chemotype Evolution to discover novel drug candidates targeting validated pathways in metabolic disease, oncology and inflammation.

Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.

Nereus Pharmaceuticals

Nereus Pharmaceuticals is a drug discovery and development company pursuing sources of chemical diversity through identifying drug candidates derived from marine microbes. With unmatched expertise in marine microbiology and integrated technologies to identify and synthesize biologically active compounds, the company's two oncology drug candidates are in Phase I clinical trials. Plinabulin (NPI-2358), a tumor vascular disrupting agent, is being evaluated for solid tumors, and a proteasome inhibitor NPI-0052 is being developed for solid tumors, lymphomas and multiple myeloma. Nereus' discovery portfolio also includes additional drug candidates for oncology, infectious diseases, and inflammation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.